Business
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes
Innovating as a global leader in cryoablation technologies, with 42 patents issued and allowedCryogenic flow control enhances the efficacy and precision of
About this update from Icecure Medical Ltd.
[{"type":"text","content":"Innovating as a global leader in cryoablation technologies, with 42 patents issued and allowedCryogenic flow control enhances the efficacy and precision of cryoablation proceduresCAESAREA, Israel, March 12, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (\"IceCure\" or the \"Company\"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has received a Notice of Allowance from the Japan Patent Office (the \"JPO\") for its patent application titled \"Cryogen Flow Control\". Once granted, the patent will be in effect until 2042. A patent for this invention is pending approval in European Union, the U.S., and other major markets.\n\nPrecise temperature control is crucial for efficacy and tissue safety in cryoablation procedures. Cryogenic flow control achieves this by utilizing sensor data to regulate the flow of cryogens, ensuring the desired temperature is reached and maintained at the distal tip of catheters and probes. This optimized cryogenic delivery enhances treatment effectiveness in cryoablation procedures. Advanced cryogen flow control systems may also offer functionalities, such as navigation and mapping support within the patient's anatomy, and be incorporated into a wide range of cryosurgical tools.\n\"We believe that cryogen flow control will be instrumental in enabling practitioners to perform accurate navigation and cryo-mapping to achieve cryoablation efficiency and expand cryoablation treatment to more clinical applications in the future,\" stated Eyal Shamir, IceCure's Chief Executive Officer. \"As a leader in cryoablation technology worldwide, we continue to innovate and build our IP portfolio. This Notice of Allowance in Japan further fortifies our position in an important market, served in partnership with our in-country distributor, Terumo.\" \nAbout ProSense®\nThe ProSense® Cryoablation System provides a minimally invasive treatment option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver.\nProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical ris...